Enorin 4000 Anti-Xa IU/0.4 ml (SC Injection)
Medicine Details
| Category | Details |
|---|---|
| Generic | Enoxaparin sodium |
| Company | Eskayef pharmaceuticals ltd |
| Also available as |
Indications
- Treatment of deep vein thrombosis, with or without pulmonary embolism
- Treatment of unstable angina and non-Q-wave myocardial infarction
- Prevention of thrombus formation in the extra-corporal circulation during haemodialysis
- Prophylaxis of venous thromboembolic disease in surgical patients
- Prophylaxis of venous thromboembolic disease in medical patients
Composition
- Enoxaparin Sodium BP 20 mg equivalent to 2000 anti-Xa III
- Enoxaparin Sodium BP 40 mg equivalent to 4000 anti-Xa III
- Enoxaparin Sodium BP 60 mg equivalent to 6000 anti-Xa IU
- Enoxaparin Sodium BP 80 mg equivalent to 8000 anti-Xa IU
Pharmacology
Low molecular weight heparin with high anti-Xa activity and low anti-lla activity. Metabolised in the liver.
Dosage
- Subcutaneously 100 anti-Xa lU/kg twice daily for 10 days
- Subcutaneously 150 anti-Xa lU/kg once daily for 10 days
- Subcutaneously 100 anti-Xa lU/kg for prevention of thrombus formation in extra corporeal circulation during hemodialysis
- Subcutaneously 2000 anti-Xa IU once daily for 7 to 10 days for general surgery patients
- Subcutaneously 4000 anti-Xa IU once daily for 7 to 10 days for orthopedic surgery patients
Administration
Instructions on injecting yourself with Enoxaparin Sodium Syringes
Interaction
Recommendation to discontinue agents affecting hemostasis prior to Enorin therapy unless strictly indicated
Contraindications
Known hypersensitivity to Enoxaparin Sodium, heparin, or other low molecular weight heparins. Active major bleeding and conditions with a high risk of uncontrolled hemorrhage.
Side Effects
Haemorrhage, Thrombocytopenia, elevations of serum aminotransferase.
Pregnancy & Lactation
Pregnancy category B. No evidence of crossing the placental barrier. Caution to be used during lactation.
Precautions & Warnings
Use with caution in conditions with increased potential for bleeding, impaired hemostasis, recent ischemic stroke, uncontrolled severe arterial hypertension, diabetic retinopathy, and recent neuro- or ophthalmologic surgery.
Use in Special Populations
- No dosage adjustment in elderly patients unless kidney function is impaired
- Observation for signs and symptoms of bleeding in patients with renal impairment
- Caution in hepatically impaired patients
Overdose Effects
Accidental overdosage may lead to hemorrhagic complications. Injection of protamine sulfate (1% solution) is recommended for neutralization.
Therapeutic Class
Parenteral anti-coagulants
Storage Conditions
Store in a cool and dry place, protect from light and moisture, below 25°C, keep out of the reach of children